 |
BioWorld-International-2006-11-29
Crucell Acquires SBL Vaccin For 40M Cash, Raises 80M
Crucell Acquires SBL Vaccin For €40M Cash, Raises €80M
Bolstering its position in the travel vaccines market, as well as its cash balance, Crucell NV completed the acquisition of SBL Vaccin AB for €39.4 million (US$51.9 million) cash and raised €80 million through a new share issue. (BioWorld International)